Link: https://links.sgx.com/1.0.0/corporate-announcements/Y4AL842SQB8DIEXM/47cc0d27ec3ce57b4a3b42c1ace1cfb54fee0bf6c694b12e20d16284def853c8

Summary:

• Takeda will discontinue its cell therapy research to focus on other therapeutic modalities, amid a strategic portfolio review.

• The company is looking for an external partner to further deploy its cell therapy technologies and programs.

• No current clinical trials are active for Takeda's cell therapy; all investments will be refocused on preclinical programs including small molecules, biologics, and antibody-drug conjugates.

• Takeda expects to recognize an impairment loss of approximately JPY 58.0 billion in Q2 FY2025, mostly related to gamma delta T-cell therapy assets.

• The majority of the impairment impact will be covered by the previously forecasted JPY 50.0 billion losses related to in-process R&D and intangible assets.

• Full details on financial impacts will be announced in Takeda’s Q2 and full-year FY2025 results, scheduled for October 30, 2025.